Pharmaceutical - Johnson & Johnson, Janssen Biotech

Filter

Popular Filters

Non-Hodgkin lymphoma market to grow to $9.2 billion

Non-Hodgkin lymphoma market to grow to $9.2 billion

29-10-2014

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

Celgene Corp.EuropeGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonMabTheraOncologyPharmaceuticalPharmacyclicsResearchRevlimidRocheUSAVelcadeZydelig

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

FDA backs Janssen’s Sylvant for rare disease

24-04-2014

The US Food and Drug Administration yesterday approved Johnson & Johnson subsidiary Janssen Biotech’s…

Janssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximabSylvantUSA

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

13-02-2014

The US Food and Drug Administration yesterday expanded the approved use of US health care giant Johnson…

ImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationUSA

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

14-11-2013

The US Food and Drug Administration yesterday approved US health care giant Johnson & Johnson’s Imbruvica…

ibrutinibImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclics

Johnson & Johnson enters novel collaborations in Europe

Johnson & Johnson enters novel collaborations in Europe

04-10-2013

Johnson & Johnson Innovation, a branch of US pharma giant Johnson & Johnson, has announced several new…

EuropeJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalResearch

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Mitsubishi Tanabe succeeds in arbitration

11-08-2013

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) says it has been awarded $117 million in an…

Anti-Arthritics/RheumaticsAsia-PacificJanssen BiotechJohnson & JohnsonLicensingMitsubishi TanabePharmaceuticalPricingRemicade

Simponi ARIA cleared by US FDA

19-07-2013

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

US FDA approves Janssen's Simponi to treat ulcerative colitis

16-05-2013

The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Janssen files BLA for IV form of Simponi for moderate-to-severe RA

20-09-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech has submitted a Biologics…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

ImmuNext partners with Janssen in up to $150 million cancer discover deal

06-09-2012

Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health…

ImmuNextJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Genmab in collaboration with Janssen for DuoBody platform

16-07-2012

Denmark-based Genmab A/S (OMX: GEN) says it has entered into a collaboration with Janssen Biotech, a…

BiotechnologyDuoBodyGenmabJanssen BiotechJohnson & JohnsonLicensingNovartisPharmaceutical

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

19-02-2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC)…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalPharmacyclics

Back to top